bluuebunny/crossref_metadata_2025_split huggingface dataset:
Determinants of Risk in Indonesian Islamic Banking: An Empirical Investigation
Authors: Haryanto Sugeng , Safriliana Retna , Ridloah Siti , Ariefudin Muhammad Umar , Khotimah Lidia Khusnul 
Published: June 2024

Islamic banking has witnessed significant growth globally, including in Indonesia, with expansions in both fund mobilization and financing activities. This study analyzes the determinants of risk in Indonesian Islamic banks from 2009 to 2022, focusing on the effects of financing-to-deposit ratio (FDR), financing growth, efficiency, company size, capital adequacy ratio (CAR), and third-party fund (DPK), on non-performing financing (NPF). Utilizing unbalanced panel data and multiple linear regression, the research finds that financing growth and efficiency have negligible effects on risk. In contrast, FDR, company size, CAR, and DPK significantly influence it. Higher FDR is linked to increased risk, while larger banks and higher CAR are associated with reduced risk. The results suggest that Islamic banks should balance financing and deposits to manage risk effectively and emphasize the importance of efficient operations and sustainable growth. This research is limited to the internal aspects of banks as determinants of FDR. Future research could examine external factors and alternative risk measures to deepen the understanding of risk in Islamic banking.==============================================================================================================ABSTRAK – Determinan Risiko Perbankan Syariah di Indonesia: Suatu Kajian Empiris. Perbankan syariah mengalami pertumbuhan yang signifikan secara global, termasuk di Indonesia, terutama dalam hal mobilisasi dana dan aktivitas pembiayaan. Studi ini menganalisis faktor-faktor penentu risiko pada perbankan syariah di Indonesia periode 2009 - 2022. Secara spesifik, kajian ini menguji pengaruh FDR, pertumbuhan pembiayaan, efisiensi, ukuran perusahaan, CAR dan DPK terhadap pembiayaan bermasalah. Dengan menggunakan data panel tidak seimbang (unbalance) dan regresi linier berganda, penelitian ini menemukan bahwa pertumbuhan pembiayaan dan efisiensi tidak memiliki pengaruh yang signifikan terhadap risiko. Sebaliknya, FDR, ukuran perusahaan, CAR, dan DPK memberikan pengaruh yang signifikan terhadapnya. FDR berkorelasi positif dengan peningkatan risiko, sementara ukuran perusahaan dan CAR berkorelasi negatif dengan pengurangan risiko. Kajian ini menyarankan agar bank-bank syariah menyeimbangkan antara pembiayaan dengan simpanan sehingga dapat mengelola risiko secara efektif dengan penekanan pada efisiensi operasional dan pertumbuhan berkelanjutan. Penelitian ini dibatasi pada aspek internal bank sebagai determinan FDR. Penelitian selanjutnya dapat mengkaji faktor-faktor eksternal dan ukuran risiko alternatif untuk memperdalam pemahaman tentang risiko dalam perbankan syariah.
1026-P: Time in Range in Relation to Diabetic Kidney Disease in Type 2 Diabetes—A Cross-Sectional Study in a Chinese Population
Authors: WANG SHIYUN , LU JINGYI , LU WEI , ZHU WEI , BAO YUQIAN , ZHOU JIAN 
Published: June 2024

Introduction & Objective: With the increased use of continuous glucose monitoring (CGM), one of the core metrics of CGMs, time in range (TIR), is emerging as a key indicator in the clinical assessment of diabetes complications. This study investigated the relationship between the TIR assessed by CGM and diabetic kidney disease (DKD).
Methods: A total of 1,533 patients with type 2 diabetes were recruited. TIR was defined as the percentage of time spent within the glucose range of 3.9-10.0 mmol/L over a 24-h period. Type 2 diabetes patients with albuminuria ≥ 30 mg/24 h or an estimated glomerular filtration rate (eGFR) ≤ 60 ml/(min × 1.73 m2) were diagnosed with DKD.
Results: The overall prevalence of DKD was 29.7% in this study. TIR was inversely correlated with diabetes duration and HbA1c (P &lt;0.001). Patients with DKD had significantly less TIR (P for trend &lt;0.001) and the prevalence of DKD decreased with ascending TIR quartiles (P for trend &lt;0.001). After adjusting for age, sex, BMI, diabetes duration, blood pressure, lipid profile, and HbA1c, patients in the highest TIR quartile were associated with a lower prevalence of DKD than those in the lowest TIR quartile (OR = 0.541 [95% CI, 0.362-0.810], P = 0.003).
Conclusion: This study reveals that TIR, a core metric assessed by CGM, is associated with DKD in type 2 diabetes.

Disclosure
S. Wang: None. J. Lu: None. W. Lu: None. W. Zhu: None. Y. Bao: None. J. Zhou: None.
1062-P: Peer Coaching Reduces Medication Barriers in African American Patients with Comorbid Diabetes and Hypertension—Results from the SEC Study
Authors: CUMMINGS DOYLE M. , ADAMS ALYSSA , PATIL SHIVAJIRAO P. , CHERRINGTON ANDREA , HALLADAY JACQUIE , SOROKA ORYSYA , BAQUERO ELIZABETH , SAFFORD MONIKA 
Published: June 2024

Introduction: Both uncontrolled diabetes and hypertension are more common among rural African Americans, and both rely on proper medication adherence for control. Patient reported medication barriers may impede medication adherence, but optimal strategies for reducing medication barriers in this population are unknown.
Methods: In a cluster randomized trial designed to improve BP control, we evaluated the impact of using trained peer coaches vs. practice-based facilitation, and the combination, compared to usual care on changes in 19 self-reported barriers to medication taking using analysis of variance. Medication barriers were computed as the total number of positive reports from a total of 19 possible barriers and this was assessed at baseline, 6-, and 12-month follow-up.
Results: The study included n=734 African American individuals with diabetes and persistently uncontrolled hypertension (SBP &gt;140mmHg); 60% female; mean age = 59 ± 11.5 yr. The most common barriers reported included not liking to take medications in general (38%), hearing about medication side effects that they were afraid of (31%), allowing medications to run out (29%) or forgetting to fill their prescription(s) on time (28%). Participants randomized to the peer coaching arm reported a significantly greater reduction in the number of medication barriers at 6-month follow-up than did those in the usual care arm (-1.08; p = 0.03). However, this difference was no longer statistically significant at 12 mo. follow-up and was not different when stratified by age (&lt;60 yrs. and ≥60 yrs.). Although systolic BP was lowered more in the peer coaching arm at 6 months than in usual care, there was no statistically significant association with changes in medication barriers.
Conclusion: These findings suggest that patients with diabetes and uncontrolled hypertension report multiple barriers with medications and that peer coaching may reduce self-reported medication barriers.

Disclosure
D.M. Cummings: None. A. Adams: None. S.P. Patil: None. A. Cherrington: Research Support; Genentech, Inc. J. Halladay: None. O. Soroka: None. E. Baquero: None. M. Safford: None.

Funding
National Heart Lung & Blood Institute (4UH3HL130691)
1082-P: Online Clinician Education Results in Performance Changes in Clinical Practice Related to Obesity Management in Patients With and Without Type 2 Diabetes
Authors: LARKIN AMY , LE ANNE 
Published: June 2024

Background: This study examined if online continuing medical education (CME) assessed if obesity evidence-based best practices would result in adoption of new clinical practices.
Methods: Clinicians participated in an online patient simulation CME activity, comprised of two different patient scenarios similar to practice. Performance was assessed with a survey 30-60 days post-education, identifying practice changes and the degree to which clinicians experience barriers to those changes. The data were collected from 3/2/2023 to 9/15/2023.
Results: There were 28 primary care physician (PCP) learners who completed the survey. Analysis showed that 96% of learners made a practice change or had practices reinforced due to education. Top 3 practice changes modified or implemented as a result of education included: Identifying patients with obesity who may benefit from anti-obesity medication (68%); Initiating anti-obesity medication early in patients meeting diagnostic criteria for obesity (68%); and screening patients for obesity (64%). Some of the main barriers to implementing practice changes identified by the learners include: Identifying patients with obesity who may benefit from anti-obesity medication; Implementing diet and exercise into practice for management of obesity; Initiating anti-obesity medication early in patients meeting diagnostic criteria for obesity; and Correctly dosing anti-obesity medication in patients meeting diagnostic criteria for obesity.
Conclusions: The practice changes identified in this assessment provide compelling evidence that participation in online CME prompts adoption of changes in practice related obesity management in patients with and without T2D.

Disclosure
A. Larkin: None. A. Le: None.

Funding
This education was supported by an independent educational grant from Lilly.
1084-P: Digital Twin Technology for Improvement in Extraglycemic Parameters—Eighteen-Months Results of the Prospective Randomized Controlled Clinical Trial
Authors: JOSHI SHASHANK , DHARMALINGAM MALA , VADAVI ARUN , KESHAVAMURTHY ASHOK , BHONSLEY SUCHITRA , THAJUDEEN MOHAMED , SHA ASMIN , SHAMANNA PARAMESH 
Published: June 2024

Utilizing the Digital Twin (DT) technology, which integrates Artificial Intelligence (AI) and the Internet of Things (IoT), this study aimed to improve extra glycemic parameters in patients with Type 2 Diabetes (T2D). The DT platform processed multidimensional data to provide individualized nutrition and health recommendations via a mobile application. Analysis was conducted on data from 218 of the 233 participants who completed a 18 months intervention with DT, showing marked improvements. The mean age and duration of diabetes were 44 years (±8.6) and 3.7 years (±2.7), respectively. Significant changes (p&lt;0.0001) were observed from baseline to 18 months in key non-glycemic parameters: Systolic BP (from 127.4 mmHg ± 11.5 to 121 mmHg ± 12.8), Diastolic BP (from 84.7 ± 7.2 to 81.6 ± 10), hs-CRP (from 2.9 mg/dl ± 4.5 to 2.2 mg/dl ± 3.1), TG/HDL ratio (from 7.9 ± 16.8 to 4.6 ± 3.6), NAFLD Fibrosis Score (from -2.3 ± 1.1 to -2.9 ± 1), and NAFLD Liver Fat Score (from 1.2 ± 2 to -0.6 ± 1.7). The integration of AI and IoT in the DT platform significantly enhanced extra glycemic parameters in T2D patients over eighteen months, indicating its transformative potential beyond traditional glycemic management.

Disclosure
S. Joshi: None. M. Dharmalingam: None. A. Vadavi: None. A. Keshavamurthy: None. S. Bhonsley: None. M. Thajudeen: None. A. Sha: None. P. Shamanna: None.
1087-P: AI as a Clinical Advisor—Benchmarking AI’s Recommendations against Clinicians’ Practices in Type 2 Diabetes Management
Authors: YOUNG CLIPPER F. , WONG SHIRLEY 
Published: June 2024

Objective: To compare clinical recommendations on type 2 diabetes management based on the ADA’s Standards of Medical Care - 2021 generated by two generative artificial intelligent (AI) platforms for internal consistency (vertically within a platform) and external consensus (horizontally between platforms and with clinicians’ clinical decisions).
Methods: A complex clinical case was chosen because the patient has developed comorbid conditions related to type 2 diabetes (e.g., myocardial infarction, stroke, chronic kidney disease). Before entering the case into each AI platform for analysis, the clinical note - chief complaint, subjective, and objective information - was edited and organized to maximize clarity and standardize the language. Following the analyses by the two AI platforms, the outcomes was analyzed qualitatively by comparing the assessment and plan written by a clinician.
Results:

Conclusion: The two generative AI platforms achieved a similar internal consistency. Regarding external consensus, both platforms focused on key points in the effectiveness theme for secondary cardiovascular prevention. Although this abstract shows one pilot case, this qualitative approach sets a foundation for future analyses as the clinical recommendations from the two generative AI platforms exhibited alignment with the notes written by clinicians (diabetes specialists).

Disclosure
C.F. Young: Other Relationship; Abbott. S. Wong: None.
1094-P: Practice Ownership and Adherence to Diabetes Guidelines
Authors: KOSTRUBSKY NICK , HARMAN JEFFREY 
Published: June 2024

Introduction & Objective: Hospital systems have recently been acquiring privately owned physician practices, converting them into vertically integrated practices. The purpose of this study is to observe if ownership of a medical practice influences adherence to clinical guidelines for management of type 1 and type 2 diabetes.
Methods: This is an observational study using pooled cross-sectional data (2014-2016, 2018-2019) from the National Ambulatory Medical Care Survey, a nationally representative probability sample of US office-based physician visits. A total of 7499 chronic routine follow ups and preventative care visits to non-integrated (solo and group physician practices) and integrated practices were analyzed to see whether guideline concordant care was provided. Measures included seven services that are recommended annually for individuals with type 1 and type 2 diabetes (HbA1c, lipid panel, serum creatinine, depression screening, influenza immunization, foot examination, BMI).
Results: Compared to non-integrated physician practices, vertically integrated practices had higher rates of hemoglobin A1C testing (odds ratio 1.59 [95% CI 1.8-2.34], P&lt;0.05), serum creatine testing (odds ratio 1.57 [95% CI 1.04-2.35], P&lt;0.05), foot examinations (odds ratio 2.14 [95% CI 1.05-4.36], P&lt;0.05), and BMI measuring (odds ratio 1.73 [95% CI 1.11-2.68], P&lt;0.05). There was no significant difference in lipid panel testing, depression screenings, or influenza immunizations.
Conclusion: Our results show that integrated medical practices have a higher adherence to diabetes practice guidelines than non-integrated practices, suggesting they may be more effective at treating chronic conditions. However, rates of services provided regardless of ownership were low. More research needs to be done on ways to improve adherence to guidelines.

Disclosure
N. Kostrubsky: None. J. Harman: None.
1117-P: Comparison between Glucose Management Indicator (GMI) with HbA1c among Patients in a Hybrid Therapeutics Care Model
Authors: CACCELLI MILENA , OZKAN CIGDEM , ZAKARIA HALA , KATTAN JOUDY , SULTAN RANA , SAID YOUSEF , HASHEMI ALI , ALMARZOOQI IHSAN 
Published: June 2024

GMI is frequently used as a substitute for HbA1c, especially when using remote monitoring, and the difference between them has a clinical relevance¹. In this study, GMI and Hba1c, along with other glycemic parameters, are examined in patients with Type 1 diabetes, Type 2 diabetes (T2D), and prediabetes using the Freestyle libre sensor during hybrid (both physical and continuous remote monitoring) therapeutic care (GluCare.Health).A retrospective observational study included 45 adults who used CGM &gt; 70 % in 3 months. Time in range (TIR), average glucose (AG), GMI, and percentage coefficient of variation (% CV) were collected from each patient's 90-day Libreview report, along with their HbA1c. Patients were monitored in-clinic and remotely through GluCare.health. HbA1c and GMI were calculated and categorized into four categories: &lt;0.1, 0.1-0.4, 0.5-0.9, and &gt; 1.Mean patient's age was 41.7 ± 16.8 years. HbA1c and GMI were different in 86.4 % of the patients. Significant differences in AG, TIR, %CV, HbA1c and GMI were observed among the 3 groups (p&lt;0.001) (Table 1). Significance between categories of HbA1c - GMI across all cohorts, with T1D showing a higher proportion of variation compared to T2D and prediabetes (p = 0.034).
HbA1c-GMI can be used in immediate decision making to manage diabetes when practicing a hybrid care model that uses continuous remote monitoring together with physical visits.

Disclosure
M. Caccelli: None. C. Ozkan: None. H. Zakaria: None. J. Kattan: None. R. Sultan: None. Y. Said: None. A. Hashemi: None. I. Almarzooqi: None.
112-OR: A Novel Function of Endothelial Insulin-Like Growth Factor-1 Receptor—Regulation of Gastrointestinal Microbiota as a Defensive Mechanism against Obesity-Induced Metabolic Dysfunction
Authors: HAYWOOD NATALIE J. , LUK CHEUKYAU , FUTERS TIMOTHY S. , REAY MELANIE , MAKAVA NATALLIA , SKROMNA ANNA , CUBBON RICHARD , KEARNEY MARK 
Published: June 2024

The gastrointestinal tract serves as an intricate ecosystem hosting trillions of microbes, known as the microbiota, and plays a crucial role in maintaining metabolic balance. Previously, we have demonstrated that mice genetically modified with endothelial IGF-1R over-expression (hIGFREO) and subjected to 8-weeks high-fat diet (HFD), exhibited reduced adipose mass, improved glucose homeostasis, and a modified microbiota compared to wildtype (WT) littermates. Therefore, our aim was to investigate the effect of transplanting microbiota from hIGFREO into C57BL/6J obese mice on glucose tolerance and insulin sensitivity. We employed fecal microbiota transplantation (FMT) to investigate the impact of the hIGFREO microbiota. Briefly, donor mice (hIGFREO and WT) were subjected to 8-weeks HFD, after this fecal pellets were collected, homogenized in 20% glycerol in PBS supplemented with 0.05% l-cysteine-HCl. Recipient obese C57BL/6J mice underwent a week of antibiotic-supplemented water to deplete the gut microbiota, followed by gavage of fecal slurry from either hIGFREO or WT donors. Obese C57BL/6J mice, subjected to hIGFREO FMT, exhibited enhanced glucose tolerance and insulin sensitivity compared to those that received WT FMT. There was no difference in body weight or circulating insulin, IGF-1, adiponectin, leptin, triglycerides or free fatty acids between the FMT groups. However, after successful FMT engraftment, the microbial biodiversity was significantly different including an increase in akkermansia muciniphila, in those mice that received hIGFREO FMT. To the best of our knowledge, this is the first study revealing the endothelium's capacity to influence the gut microbiota. Additionally, we demonstrate the involvement of endothelial IGF-1R in the beneficial remodelling of the gut microbiota, which leads to improved whole body glucose tolerance and insulin sensitivity.

Disclosure
N.J. Haywood: None. C. Luk: None. T.S. Futers: None. M. Reay: None. N. Makava: None. A. Skromna: None. R. Cubbon: Speaker's Bureau; Janssen Pharmaceuticals, Inc. M. Kearney: None.

Funding
British Heart Foundation
1120-P: Diabetestal—Danish Diabetes Dashboard—A Tool to Monitor and Improve the Quality of Diabetes Treatment
Authors: CAYUELAS MATEU NURIA , THYBO TANJA 
Published: June 2024

Introduction & Objective: No publicly accessible and highly updated database on diabetes treatment and outcomes has been available before in Denmark. The aim is to provide data to help improve the health of people living with diabetes.
Methods: Diabetestal, developed by the Danish Diabetes Association, is a quarterly updated quality database of all people living with diabetes in Denmark. Diabetestal links individual health records from several registers that are internationally recognized for their high validity and quality, e.g. the Patient Register, The Clinical Laboratory Information Register and The Prescription Registry. Data includes lab measurements, drug purchases, accessories, diabetes-related complications, glycemic control separately for demography, diabetes duration and residence etc.
Results: Diabetestal integrates clinical practice guidelines through an open, intuitive, chart-based, customizable user experience, enabling the analysis of geographical inequalities in treatment across time, e.g. therapeutic inertia in Danmark has improved while regional inequalities in treatment persist, as depict in the graph.
Conclusion: Diabetestal may help health professionals highlight trends or problems and enable them to make informed decisions and thereby improve adherence to quality guidelines and help improve outcomes for people living with diabetes. www.diabetestal.nu

Disclosure
N. Cayuelas Mateu: Research Support; Novo Nordisk A/S, Bayer Inc., Boehringer-Ingelheim, Sanofi, AstraZeneca, Abbott, Abbott Diagnostics. T. Thybo: Research Support; Novo Nordisk A/S, Bayer Inc., Boehringer-Ingelheim, Sanofi, AstraZeneca, Abbott, Abbott Diagnostics.
1122-P: Post-discharge Scheduled Appointments and Clinical Outcomes in Patients with Diabetes and Low Socioeconomic Status Community
Authors: TEHRANIAN SHAHRZAD , MON SANN 
Published: June 2024

Introduction and Objective: Diabetes mellitus (DM) management presents significant healthcare challenges, and optimizing post-hospitalization care is crucial. This study explores the impact of scheduled follow-up appointments with an endocrinologist on the glycemic status of diabetic patients discharged from the hospital.
Methods: We retrospectively included adult patients with DM who were admitted to UPMC McKeesport Hospital for any reason from March 2018 to September 2022. The patients were divided into group A, who were provided with scheduled follow-up appointments, and group B, the patients who were given contact information to schedule their own appointments.
Results: Forty patients, median age of 60 years (IQR: 50.2-66.0), male 25 (62%) were included. In group A, the median A1C levels at admission and 90-day post-discharge were 10.9% (IQR: 7.9-13.9) and 7.6% (IQR: 5.4-9.4), respectively. In group B, the corresponding characteristics were 10.6% (IQR: 8.2-12.1) and 7.5% (IQR: 5.8-9.4). There was no relation between post-discharge scheduled appointments and readmission rate in 90 days (P &gt; 0.05). There was a significant relation between readmission rate and A1C level in 90 days (P &lt; 0.05). Among those attending follow-up visits with an endocrinologist, 56% experienced an improvement in A1C levels of at least 0.5% in 90 days.
Conclusion: Follow-up appointment with endocrine clinic has the potential to lead to improved clinical outcomes as evidenced by reduction in A1C level.

Disclosure
S. Tehranian: None. S. Mon: None.